Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of fall allergies

Allergy and Asthma Proceedings

Volumn 19, Issue 3, 1998, Pages 135-141

  Bronsky, Edwin A ^a  

^a Intemountain Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; DRUG DERIVATIVE; FEXOFENADINE; TERFENADINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; HAY FEVER; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; RHINITIS, ALLERGIC, SEASONAL; SINGLE-BLIND METHOD; TERFENADINE; TREATMENT OUTCOME;

EID: 0032058628     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/108854198778604112     Document Type: Article

References (3)

1. Russell T, Stoltz M, Eller M, et al. Acute and subchronic dose tolerance of fexofenadine HCl in healthy male patients (Abstract) Presented at the annual scientific sessions of the American College of Allergy, Asthma, and Immunology, 1995.
2. Day J, Briscoe M, Welsh A, et al. Onset of action, efficacy, and safety of a single dose of fexofenadine HCl for ragweed allergy using an environmental exposure unit. Ann Allergy. In press.
3. 1 antagonists. Ann Allergy 66:5-22, 1991.